Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Interleukin-6 As A Predictive Factor Of Pathological Response To Flot Regimen Systemic Treatment In Locally Advanced Gastroesophageal Junction Or Gastric Cancer Patients

Interleukin-6 as a Predictive Factor of Pathological Response to FLOT Regimen Systemic Treatment in Locally Advanced Gastroesophageal Junction or Gastric Cancer Patients

Katarzyna Marcisz-Grzanka1, Beata Kotowicz2, Aleksandra Nowak3

  • 1Department of Clinical Oncology and Radiotherapy, Maria Sklodowska-Curie National Research Institute of Oncology (MSCNRIO), Wawelska 15, 02-034 Warsaw, Poland.

Cancers
|February 24, 2024

Related Experiment Videos

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors
03:05

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors

Published on: February 16, 2024

1.1K
Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

434
Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

7.0K

View abstract on PubMed

Summary
This summary is machine-generated.

Interleukin-6 (IL-6) serum levels before and during neoadjuvant chemotherapy (NAC) can predict treatment response in gastric cancer patients. Lower IL-6 levels indicate a better pathological response to NAC.

Area of Science:

  • Oncology
  • Gastroenterology
  • Biomarker Discovery

Background:

  • Perioperative treatment is standard for locally advanced gastric and gastroesophageal junction (GEJ) cancer.
  • Neoadjuvant chemotherapy (NAC) response rates are limited, with no current biomarkers for predicting efficacy.
  • Early identification of treatment response biomarkers is crucial for personalized therapy.

Purpose of the Study:

  • To identify serum biomarkers that predict early response to neoadjuvant chemotherapy (NAC) in gastric and GEJ cancer patients.
  • To evaluate the potential of Interleukin-6 (IL-6) as a predictive biomarker for NAC efficacy.

Main Methods:

  • Prospective study involving 71 gastric cancer patients and 15 healthy volunteers.
  • Measured complete blood count, CEA, CA125, CA19.9, fibrinogen, CTCs, and interleukins (IL-1β, IL-6, IL-8, IL-10) at baseline and during chemotherapy cycles.
Keywords:
FLOT regimenIL-6gastric cancergastroesophageal junction cancer

Related Experiment Videos

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors
03:05

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors

Published on: February 16, 2024

1.1K
Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

434
Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

7.0K
  • Analyzed serum IL-6 levels in relation to pathological response (pCR, ypN status) after NAC.

    • Main Results:

    • Serum Interleukin-6 (IL-6) levels were the only statistically significant predictor of NAC response.
    • Lower IL-6 levels before Cycle 2 (C2) correlated with complete pathological response (pCR).
    • Elevated IL-6 levels before Cycle 1 (C1) were associated with a higher likelihood of positive lymph node metastasis (ypN+).

    Conclusions:

    • Elevated IL-6 levels before NAC initiation and before C2 may predict pathological response.
    • IL-6 serves as a potential biomarker for assessing early treatment efficacy in gastric cancer patients undergoing NAC.
    • This finding could aid in tailoring treatment strategies for improved patient outcomes.
    predictive biomarker